The World Anti-Doping Agency (WADA) has announced the postponement of the 2021 Therapeutic Use Exemption (TUE) Symposium to 2022 because of "considerable uncertainty" caused by the coronavirus pandemic.
The meeting was due to take place in Incheon in South Korea from April 22 to 23 next year.
But WADA and its host partner the Korean Anti-Doping Agency (KADA) have decided to delay it by 12 months, with the session now set for April 21 to 22 in 2022.
The decision follows WADA's announcement in November to postpone the Annual Symposium, scheduled to be held in March 2021 in Lausanne in Switzerland, due to the global health crisis.
Alan Vernec, medical director of WADA, said the coronavirus situation made it difficult to travel to the meeting.
"We are disappointed about postponing the TUE Symposium yet, despite the optimism surrounding the new COVID-19 vaccines, there still remains considerable uncertainty as to the course of the pandemic and, therefore, the ability for all participants to safely travel and congregate in April 2021," said Vernec.
"WADA and KADA are committed to offering a safe and productive experience for all; and therefore, we will be ready to welcome participants to Incheon in April 2022."
WADA said the primary objective of the symposium is to standardise the approach to TUEs, which ensure athletes with legitimate medical conditions may participate in sport despite their need for a prohibited substance or method.
The event is set to feature discussions on the revised international standard for TUEs, which is due to come into effect on January 1.
Interactive discussions will also be held on medical cases, medico-legal issues, retroactive TUEs and the challenges regarding the global harmonisation of practices, according to WADA.
"The goal is to ensure that fairness is maintained, and athletes are afforded similar opportunities, regardless of their sport, geographical location or specific medical issues," a statement from WADA added.
WADA said it was also planning to hold short webinars on the 2021 international standard for TUEs, including medico-legal issues and cases with more details set to be announced in the coming months.